The ASTCT-NMDP ACCESS Initiative: A Collaboration to Address and Sustain Equal Outcomes for All across the Hematopoietic Cell Transplantation and Cellular Therapy Ecosystem

Jeffery J. Auletta(Nationwide Children's Hospital), Stella M. Davies(Cincinnati Children's Hospital Medical Center), Jessica Knutson(National Marrow Donor Program), Femina Ajayi-Hackworth(National Marrow Donor Program), Brenda M. Sandmaier(University of Washington), Navneet S. Majhail(Sarah Cannon), Erica Jensen(National Marrow Donor Program), Eneida R. Nemecek(Oregon Health & Science University)
Transplantation and Cellular Therapy
September 30, 2022
10.1016/j.jtct.2022.09.020
Cited by 46

Related Papers

Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
|New England Journal of Medicine|2018|5.7k
HLA-Haploidentical Bone Marrow Transplantation for Hematologic Malignancies Using Nonmyeloablative Conditioning and High-Dose, Posttransplantation Cyclophosphamide
|Biology of Blood and Marrow Transplantation|2008|1.9k
Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects
|Blood|2001|1.4k
Genetic mechanisms of target antigen loss in CAR19 therapy of acute lymphoblastic leukemia
|Nature Medicine|2018|577
Early cytomegalovirus reactivation remains associated with increased transplant-related mortality in the current era: a CIBMTR analysis
|Blood|2016|554